One-year outcomes of polyacrylamide hydrogel (Bulkamid) injection in women with stress and mixed urinary incontinence

IF 2.8 2区医学 Q2 UROLOGY & NEPHROLOGY

World Journal of Urology Pub Date : 2024-09-11 DOI:10.1007/s00345-024-05221-9

Alessandro Uleri, Fabienne Marchand, Arnaud Cherasse, William Berchiche, Christopher Agüero, Mamadou B. Bah, Michael Baboudjian, Marc Fourmarier

{"title":"One-year outcomes of polyacrylamide hydrogel (Bulkamid) injection in women with stress and mixed urinary incontinence","authors":"Alessandro Uleri, Fabienne Marchand, Arnaud Cherasse, William Berchiche, Christopher Agüero, Mamadou B. Bah, Michael Baboudjian, Marc Fourmarier","doi":"10.1007/s00345-024-05221-9","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study aimed to evaluate the efficacy and safety following treatment with Bulkamid for stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (MUI).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We retrospectively analyzed data of women diagnosed with SUI or stress-predominant MUI who underwent Bulkamid periurethral injection between November 2020 and January 2023 and completed 12 months of follow-up. The primary outcome of the study was to assess patient satisfaction, which was measured on a four-point scale, ranging from cured to worse, and through validated questionaries such as the International Consultation on Incontinence Questionnaire-short Form (ICIQ-UI SF) and Contilife Quality of Life questionnaire.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 70 patients included, 41 (59%) had MUI with predominant stress incontinence. Median age was 59 years (IQR 47–75), with a median BMI of 25 (18–40) and a median number of pregnancies of 2 (0–4). Forty-seven (67%) procedures were performed under sedation and 23 (33%) under local anesthesia. Forty-three (69%) women reported feeling cured or improved at 12 months follow-up and among them, 25 (40%) reported feeling cured. A total of 16 (23%) patients were subsequently treated, in detail 11 (16%) patients underwent MUS positioning, and 5 (7%) had an additional injection of Bulkamid. ICIQ and Contilife QoL showed a significant improvement at 1, 3, 6, and 12 months (all <i>p</i> < 0.001).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Bulkamid injections are an effective and safe treatment option for women with SUI or stress-predominant MUI, providing good outcomes at 12 months.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00345-024-05221-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This study aimed to evaluate the efficacy and safety following treatment with Bulkamid for stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (MUI).

Methods

We retrospectively analyzed data of women diagnosed with SUI or stress-predominant MUI who underwent Bulkamid periurethral injection between November 2020 and January 2023 and completed 12 months of follow-up. The primary outcome of the study was to assess patient satisfaction, which was measured on a four-point scale, ranging from cured to worse, and through validated questionaries such as the International Consultation on Incontinence Questionnaire-short Form (ICIQ-UI SF) and Contilife Quality of Life questionnaire.

Results

Of the 70 patients included, 41 (59%) had MUI with predominant stress incontinence. Median age was 59 years (IQR 47–75), with a median BMI of 25 (18–40) and a median number of pregnancies of 2 (0–4). Forty-seven (67%) procedures were performed under sedation and 23 (33%) under local anesthesia. Forty-three (69%) women reported feeling cured or improved at 12 months follow-up and among them, 25 (40%) reported feeling cured. A total of 16 (23%) patients were subsequently treated, in detail 11 (16%) patients underwent MUS positioning, and 5 (7%) had an additional injection of Bulkamid. ICIQ and Contilife QoL showed a significant improvement at 1, 3, 6, and 12 months (all p < 0.001).

Conclusions

Bulkamid injections are an effective and safe treatment option for women with SUI or stress-predominant MUI, providing good outcomes at 12 months.

Abstract Image

查看原文本刊更多论文

聚丙烯酰胺水凝胶（Bulkamid）注射治疗压力性和混合性尿失禁妇女一年的疗效

方法我们回顾性分析了 2020 年 11 月至 2023 年 1 月期间接受 Bulkamid 尿道周围注射并完成 12 个月随访的被诊断为 SUI 或压力主导型混合性尿失禁的女性患者的数据。研究的主要结果是评估患者的满意度，满意度采用四点量表进行测量，从治愈到恶化不等，并通过尿失禁国际咨询问卷-短表（ICIQ-UI SF）和Contilife生活质量问卷等经过验证的问卷进行测量。结果在纳入的70名患者中，41人（59%）患有以压力性尿失禁为主的MUI。中位年龄为 59 岁（IQR 47-75），中位体重指数为 25（18-40），中位怀孕次数为 2（0-4）次。47例（67%）手术在镇静状态下进行，23例（33%）在局部麻醉状态下进行。43名（69%）妇女在12个月的随访中表示感觉痊愈或有所改善，其中25名（40%）表示感觉痊愈。共有 16 名（23%）患者接受了后续治疗，其中 11 名（16%）接受了 MUS 定位，5 名（7%）额外注射了 Bulkamid。ICIQ和Contilife QoL在1、3、6和12个月时均有显著改善（均为p < 0.001）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Urology 医学-泌尿学与肾脏学

CiteScore

6.80

自引率

8.80%

发文量

317

审稿时长

4-8 weeks

期刊介绍： The WORLD JOURNAL OF UROLOGY conveys regularly the essential results of urological research and their practical and clinical relevance to a broad audience of urologists in research and clinical practice. In order to guarantee a balanced program, articles are published to reflect the developments in all fields of urology on an internationally advanced level. Each issue treats a main topic in review articles of invited international experts. Free papers are unrelated articles to the main topic.